LINTONPHARM
27.5.2022 15:02:13 CEST | Business Wire | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：
e16102
Abstract Title：
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1] . Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2] . Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe Announces Closing of Global Credit Facility of Up to $139 Million27.8.2026 13:47:00 CEST | Press release
New Credit Facility Enhances Global Financial Flexibility to Support Growth Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a leading global provider of engineered piping and leak detection solutions for energy, infrastructure and industrial markets, today announced the closing of a new global credit facility with J.P. Morgan consists of a $75.0 million revolving credit facility and a $14.0 million term loan facility, and allows the Company access to an additional $50.0 million in incremental capacity. The new facility replaces and consolidates multiple existing credit facilities maintained by the Company and its subsidiaries across various jurisdictions, creating a more streamlined and centralized financing structure for Perma-Pipe’s global operations. It also provides Perma-Pipe with significantly increased financial capacity, enhanced liquidity and greater flexibility to support working capital requirements, letters of credit, strategic invest
Uniphore and Tech Mahindra Partner to Deliver an Agentic AI Factory for the Enterprise27.8.2026 13:45:00 CEST | Press release
Partnership enables the development of domain-specific Small Language Models and AI agents on Uniphore's Business AI Cloud for enterprise clients across EMEA and North America. Uniphore, the Business AI Company, and Tech Mahindra (NSE: TECHM), a leading global provider of technology consulting and digital solutions to enterprises across industries, today announced a partnership to co-build and deliver agentic AI solutions for enterprise clients globally. The partnership combines Uniphore's Business AI Cloud (BAIC) platform with Tech Mahindra's deep digital business transformation expertise and global delivery capabilities, establishing an Agentic AI Factory to accelerate AI adoption at scale within Tech Mahindra and for its customer industry verticals. As part of the partnership, Tech Mahindra will integrate Uniphore's BAIC platform into its Agentic AI Factory, enabling the development, deployment and management of purpose-built small-language models (SLMs), AI agents and industry-spec
Kioxia and Sandisk to Invest Over $31 Billion in Japan, Extending Leadership in Memory Industry27.8.2026 13:39:00 CEST | Press release
Continued investments through 2032 will further strengthen the companies’ long-standing joint venture and drive meaningful, multi-year flash memory-supplyInvestments align with economic policy goals of Japanese government and reflect strong U.S. – Japan relations Kioxia Corporation, a subsidiary of Kioxia Holdings Corporation (TOKYO: 285A) and Sandisk Corporation (NASDAQ: SNDK) today announced anticipated significant investments in Japan, totaling over $31 billion (approximately 5 trillion yen) contingent upon government support. The investments through 2032 will continue to strengthen the Kioxia and Sandisk partnership, one of the most successful joint ventures across any industry. The partnership has helped drive decades of NAND flash memory innovation and invested over $50 billion (approximately 9 trillion yen) in Japan over the past 25 years. Kioxia and Sandisk will continue to deliver leading technology to support the growing demands of an AI and a data-driven world. This press re
Kioxia to Expand 3D Flash Memory Production Capacity with the New Fab3 at Kitakami Plant27.8.2026 13:20:00 CEST | Press release
Kioxia Corporation, a world leader in memory solutions, announced today that it has commenced site preparation and other related work for the construction of Fab3, a new state-of-the-art manufacturing facility at the Kitakami Plant in Iwate Prefecture, Japan, to expand production capacity for advanced three-dimensional flash memory BiCS FLASH™. Fab3 will be constructed on land south of Fab2, targeting operations to commence in fiscal 2029. The flash memory market is expected to continue to expand significantly in the medium to long term, driven by agentic AI, physical AI, and on-device AI. Through the construction of Fab3, Kioxia aims to meet rising market demand by expanding production and ensuring stable supply of cutting-edge flash memory products. Detailed plans for Fab3 regarding construction schedule and equipment investments will be determined based on market trends. Investment plans for Fab3 are contingent upon government support. Under its mission to “uplift the world with ‘me
Quaise Energy Closes $180 Million Series B with $35 Million Investment from Nabors Industries and Strategic Framework to Build World's First Superhot Geothermal Power Plant27.8.2026 13:05:00 CEST | Press release
Final close of Series B to advance the commercialization of superhot geothermal energy, funding Project Obsidian and the continued development of Quaise’s millimeter wave drilling system Nabors Industries and Quaise deepen relationship with strategic framework agreement spanning drilling operations, technology integration and commercial development Series B brings Quaise's total funding to date to $280 million Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the final close of its Series B, raising a total of $180 million in equity financing, including a $35 million investment from Nabors Industries (NYSE: NBR), one of the world's largest land drilling contractors and a long-standing partner to Quaise. Nabors has also entered into a strategic framework agreement that supports Quaise’s mission to make superhot geothermal a commercial reality, beginning with the development of Project Obsidian, the world’s first superhot geothermal power pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom